Categories
Change Password!
Reset Password!
Osteoarthritis (OA) is the very common chronic joint disease that is usually diagnosed at relatively advanced stages when there is irreparable damage to the joint(s).
This recent study enlightens two immunoassays that can be
helpful in detecting endogenous peptide biomarkers and shows a great
specificity for osteoarthritis. An early diagnosis of biochemical tests can be
helpful in the prevention of OA.
Osteoarthritis (OA) is the very common chronic joint
disease that is usually diagnosed at relatively advanced stages when there is
irreparable damage to the joint(s). Recently, two novel biomarkers have been
identified, C3f and V65 which appear to be OA-specific and therefore potential
markers of early disease. The development of immunoassays has been reported for
the quantitative measure of these two novel biomarkers.
Monoclonal and polyclonal antibodies were generated by
immunizing rabbits and mouse respectively with peptide-carrier conjugates of
V65 and C3f. Assays were validated using serum from OA patients and controls
and the affinity-purified antibodies were used for immunoassays development.
The developed ELISA showed very sharp recovery of about
96% (up to) for C3f and V65 peptides depending on serum dilutions with a
coefficient of variation (CV) <10%. The inter- and intra- assay CVs for V65
and C3f were 4.2–10.3% and 1.3–10.8%
respectively. Both the assays were insensitive for measurements of the peptides
in patients, and the use of different signal amplification systems still was
not able to increase the sensitivity of the assay
Two immunoassays are developed for measurements of C3f
and V65 peptides biomarkers discovered by our earlier proteomic study. These
assays could detect the endogenous peptides in serum samples from patients and
controls but lacked sensitivity for accurate measurements of the peptides in OA
patients. The study also highlighted the difficulties and challenges of
validating biomarker from proteomic studies and demonstrated how to overcome
the technical challenges associated with the development
PLoS One. 2017 Jul 17;12(7):e0181334
Development and validation of novel biomarker assays for osteoarthritis
Khadija Ourradi et al.
Comments (0)